



ATTACHMENT A

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.-22. (Canceled)

14. (Currently amended) A method of treating or preventing an *S. epidermidis* infection in a patient comprising administering to the patient an antibody capable of binding to amino acids 51-598 of SEQ ID NO:10 in an amount effective to inhibit fibrinogen binding to *S. epidermidis*.

15. Canceled.

16. (Previously presented) The method of Claim 14, wherein the ligand binding A region is encoded by a nucleic acid having the sequence of nucleotides 151-1794 in SEQ ID NO:7.

17. (Original) The method of Claim 14, wherein antibody is administered in the form of a pharmaceutical composition comprising the antibody in an amount effective to inhibit fibrinogen binding and a pharmaceutically acceptable carrier.

18-22. (Canceled)

23. (New) A method of inhibiting *S. epidermidis* binding to a host cell, medical device or a polymeric biomaterial comprising administering to a patient, a medical device or a polymeric biomaterial a pharmaceutical composition comprising an antibody capable of binding to amino acids 51-598 of SEQ ID NO:10 in an amount effective to inhibit binding of *S. epidermidis* to a host cell, medical device or a polymeric biomaterial, and a pharmaceutically acceptable carrier.